Sponsor:
Dana-Farber Cancer Institute
Code:
NCT04468061
Conditions
Breast Cancer
Triple Negative Breast Cancer
PD-L1 Negative
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sacituzumab Govitecan
Pembrolizumab
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-07. This information was provided to ClinicalTrials.gov by Dana-Farber Cancer Institute on 2025-08-05.